The package insert for any prescription medication is a comprehensive document providing crucial information for healthcare professionals and patients.
Understanding the Elacestrant (Orserdu) Package Insert
The package insert for any prescription medication is a comprehensive document providing crucial information for healthcare professionals and patients. For Elacestrant, marketed under the brand name Orserdu, understanding its prescribing information is vital for safe and effective use. This article offers a guide to the key details typically found within the official Elacestrant package insert, helping to clarify its purpose, administration, and safety considerations. Please note that this content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider and refer to the official prescribing information for complete details and personalized guidance.
What is Elacestrant (Orserdu)?
Elacestrant (Orserdu) is an oral selective estrogen receptor degrader (SERD) approved for the treatment of certain types of advanced or metastatic breast cancer. It specifically targets estrogen receptors, aiming to block their activity and degrade them, thereby inhibiting the growth of hormone receptor-positive breast cancer cells. This medication is a significant option for patients whose cancer has progressed following prior endocrine therapy.
Key Sections of the Elacestrant Package Insert
The official Elacestrant package insert, also known as the full prescribing information, is a highly detailed document structured to provide all necessary data regarding the drug. Key sections typically include:
- Indications and Usage: Defines the specific conditions for which Elacestrant is approved.
- Dosage and Administration: Provides instructions on how much medication to take, how often, and any special considerations for administration.
- Contraindications: Lists situations where Elacestrant should not be used.
- Warnings and Precautions: Highlights serious potential risks and necessary monitoring.
- Adverse Reactions: Details common and less common side effects observed in clinical trials.
- Drug Interactions: Describes how Elacestrant may interact with other medications.
- Use in Specific Populations: Information regarding use in pregnant, lactating, pediatric, or geriatric patients, and those with kidney or liver impairment.
Elacestrant: Indications and Usage
Elacestrant (Orserdu) is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer with an activating ESR1 mutation, as detected by an FDA-approved test, whose disease has progressed following at least one line of endocrine therapy.
Dosage and Administration Information
The recommended dosage of Elacestrant is typically taken orally once daily, with food. It is crucial to follow your prescribing physician's instructions precisely regarding dose, timing, and any dose modifications that may be necessary based on individual response or side effects. Do not alter your dosage or stop treatment without consulting your doctor.
Important Safety Information and Warnings
The package insert emphasizes several important warnings and precautions associated with Elacestrant. These typically include:
Embryo-Fetal Toxicity
Elacestrant can cause fetal harm when administered to a pregnant woman. Patients should be advised of the potential risk to a fetus and use effective contraception during treatment and for a specified period after the last dose.
Hypercholesterolemia and Hypertriglyceridemia
Increases in cholesterol and triglycerides have been observed with Elacestrant. Lipid levels should be monitored prior to initiating treatment and periodically thereafter.
Potential Adverse Reactions (Side Effects)
Like all medications, Elacestrant can cause side effects. The package insert details the frequency and severity of adverse reactions reported in clinical trials. Common side effects may include:
- Musculoskeletal pain (arthralgia)
- Nausea
- Fatigue
- Vomiting
- Decreased appetite
- Diarrhea
- Headache
- Constipation
- Abdominal pain
- Hot flush
- Dyspepsia
Patients should report any new or worsening side effects to their healthcare provider promptly.
Drug Interactions
Elacestrant is metabolized by the enzyme CYP3A4. Therefore, co-administration with strong CYP3A4 inhibitors (which can increase Elacestrant exposure) or strong CYP3A4 inducers (which can decrease Elacestrant exposure) should generally be avoided or managed with dose adjustments as recommended in the official prescribing information. Always inform your doctor about all medications, supplements, and herbal products you are currently taking.
Consult Your Healthcare Provider
While this article provides an overview of the Elacestrant package insert, it is not a substitute for the official prescribing information or professional medical advice. For complete and up-to-date details, always refer to the full package insert provided by the manufacturer or accessed through official regulatory sources. Your oncologist or healthcare team can provide personalized information, discuss potential risks and benefits, and ensure Elacestrant is the appropriate treatment for your specific condition.